Purvalanol A (CDK Inhibitor) Market Report 2026: Expanding Molecular Biology and Cancer Research Fuelling Market Growth

The Purvalanol A (CDK Inhibitor) market has demonstrated impressive growth, expanding from $0.64 billion in 2025 to $0.7 ...

Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or ...

Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced ...
MedPage Today

Chemo-Free Regimen for Endometrial Cancer Produces Durable Responses, Favorable PFS

A chemotherapy-free regimen for advanced/recurrent endometrial cancer achieved durable disease control in a substantial ...

Understanding how plants pause and restart growth can help develop climate-resilient crops

When plants face biting cold, floods or parched soil, they can’t run away or seek shelter like animals. Instead, they have to ...
CURE

The Role of CDK4/6 Inhibitors in ER-Positive, HER2-Negative Metastatic Breast Cancer

In this segment, Dr. Gregory Vidal explains why CDK4/6 inhibitors are commonly added to endocrine therapy in the treatment of ...
The Bakersfield Californian

Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of ...

Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the ...

Precision work prior to cell division: How enzymes optimize DNA structure

Before a cell can divide, it has to precisely duplicate its entire genetic information. However, the DNA in the cell exists ...